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Protein arginine methyltransferases (PRMTs) catalyse the transfer of methyl groups to arginine residues in 
proteins. PRMT inhibitors are novel, promising drugs against cancer that are currently in clinical trials, which 
include oral administration of the drugs. However, off-target activities of systemically available PRMT inhibitors 
have not yet been investigated. In this work, we study the relevance of arginine methylation in platelets and 
investigate the effect of PRMT inhibitors on platelet function and on the expression of relevant platelet receptors. 
We show that (1) key platelet proteins are modified by arginine methylation, (2) incubation of human platelets 
with PRMT inhibitors for 4 hours results in impaired capacity of platelets to aggregate in response to thrombin 
and collagen, with IC50 values in the µM range, and (3) treatment with PRMT inhibitors leads to decreased 
membrane expression and reduced activation of the critical platelet integrin αIIbβ3. Our contribution opens new 
avenues for research on arginine methylation in platelets, including the repurposing of arginine methylation 
inhibitors as novel antiplatelet drugs. We also recommend that current and future clinical trials with PRMT 
inhibitors consider any adverse effects associated with platelet inhibition of these emerging anti-cancer drugs. 
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Platelets, or thrombocytes, are small anucleate discoid cells of 3 μm in diameter and key components of normal 
haemostasis.1 In the event of injury, platelets adhere to the injured vessel wall, aggregate with other platelets 
and combine with soluble fibrinogen and insoluble fibrin to form a platelet plug. Platelets are the second most 
numerous cells in circulating blood, typically present in 150-440x106 cells/ml and have an average life span of 
5-10 days.2 
Platelets can be activated by agonists such as thrombin, collagen, adenosine diphosphate (ADP) and von 
Willebrand factor (vWF). Platelet membranes contain glycoprotein receptors that induce signalling mechanisms 
inside the cell upon ligand binding to trigger platelet activation. Activated platelets undergo actin cytoskeletal 
rearrangements to form membrane extensions, called lamellipodia, which facilitate platelet adhesion to vascular 
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wall structures by increasing the surface area of the platelet.3 Platelets can also adhere to each other through the 
formation of inter-platelet bridges, in a process known as platelet aggregation.4 Platelet aggregation is dependent 
on the activity of the αIIbβ3 receptor, the most abundant integrin in human platelets.
5 Activation of the αIIbβ3 
fibrinogen receptor is the final step in the activation process and the first step towards aggregation, which is 
amplified by secretion of platelet dense and alpha granules.6 
Although platelet function is vital to haemostasis, pharmaceutical interventions to decrease the activity of 
platelets can be very useful in the clinical setting. Patients at risk of cardiovascular disease, including myocardial 
infarction and stroke, can benefit from antiplatelet therapies that reduce the risk of occlusion of a blood vessel by 
a thrombus, leading to ischemia. Antiplatelet drugs interfere with mechanisms of platelet activation or 
aggregation and include aspirin, P2Y12 receptor blockers (such as clopidogrel and ticagrelor) and αIIbβ3 
antagonists.7 Antiplatelet drugs have gained visibility in the context of the COVID-19 pandemic,8 because overall 
17% of COVID-19 patients suffer from venous thromboembolisms.9 Although antiplatelet drugs are widely used 
in the clinics, there is a subtle balancing act between the desirable antiplatelet effects of therapy in patients and a 
higher risk of bleeding.10 
In a normal physiology setting, the premature activation of platelets is inhibited by endogenous substances 
secreted by endothelial cells, namely prostacyclin (PGI2) and nitric oxide (NO). PGI2 and NO inhibit platelet 
function through activation of adenylyl cyclase and guanylyl cyclase, respectively, and the corresponding cyclic 
nucleotide-dependent protein kinase A (PKA) and G (PKG) signalling.11 Vasodilator-stimulated phosphoprotein 
(VASP) is a key player in platelet signalling pathways through its role as an actin cytoskeleton regulator,12 and 
phosphorylation of VASP (by PKA and PKG) is a gold standard of platelet quiescence.13 
Protein post-translational modifications are key players in signal transduction thanks to their ability to 
change protein activity, localisation and interactions. Arginine methylation (ArgMe) of proteins consists of the 
transfer of a methyl group (CH3) from S-adenosyl-L-methionine onto the side chain guanidino nitrogen of 
arginine, in an enzymatic reaction catalysed by protein arginine methyltransferases (PRMTs).14 The addition of 
a CH3 group can affect hydrogen bonding interactions of the recipient arginine and produces bulkier and more 
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hydrophobic methylarginine residues.15 There are three types of PRMTs, each responsible for a different ArgMe 
end-product: Type I PRMTs lead to asymmetric dimethylarginine (ADMA); Type II PRMTs produce symmetric 
dimethylarginine (SDMA); and Type III PRMTs form monomethyl arginine (MMA) only. MMA is produced by 
all three PRMT types and is often seen as a stable, but intermediate, product in Types I and II PRMT reactions. 
Type I PRMTs include PRMT1, -2, -3, -4, -6 and -8. PRMT5 and -9 are type II PRMTs. PRMT7 is the only type 
III PRMT.16 It is accepted that most of the ArgMe activity in mammalian cells can be attributed to PRMT1.17, 18 
PRMTs are key epigenetic regulators or “writers” of epigenetic methylation marks and PRMT inhibitors 
have been developed over the last two decades to pharmacologically modulate PRMT activity and regulate gene 
expression.14  Recently, PRMT inhibitors have entered clinical trials in the oncology setting (identifiers: 
NCT03666988, NCT02783300, NCT03614728, NCT03573310, NCT03854227 and NCT04089449).14 Most 
PRMT inhibitors in clinical trials are administered orally, and therefore systemically.19, 20 This raises the obvious 
question of possible off-target, side effects of ArgMe inhibition in any cell type. There is little documentation 
available on this issue, but preclinical experiments with rats and dogs revealed moderate changes to 
haematological profiles, including on the number of platelets, when the animals where treated with the Type I 
PRMT inhibitor GSK3368715 for up to 28 days.19 It is therefore timely to investigate any side effects of PRMT 
inhibitors on platelet function. Furthermore, the extent and role of ArgMe has not been explored in platelets. The 
aims of the present paper are (1) to reveal the relevance of ArgMe in platelets by describing the platelet “arginine 
methylome” and (2) to investigate the effect of ArgMe inhibition on platelet function by incubating platelets with 
PRMT inhibitors.  
Results 
The platelet arginine methylome reveals key roles in platelet function 
To gain an understanding of the scope of protein ArgMe in platelets, we systematically searched available 
proteomics datasets of platelets for ArgMe. We searched the ProteomeXchange repository for the term “platelet” 
and identified 13 ProteomeXchange datasets (PXD) suitable for further analysis (Figure 1A and Suppl. Table 
S1). Using our recently published proteomics workflow,21 we identified proteins modified by ArgMe in each of 
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the 13 projects. We then defined the platelet arginine methylome as those ArgMe sites that were common to three 
or more projects and we counted 96 sites in 64 proteins that fulfilled this criterium (Suppl. Table S2), including 
in each of the two components of the αIIbβ3 receptor. 
Analysis of GO terms enriched in this subset of 64 proteins against the platelet proteome background 
(8527 proteins identified in the 13 PXD projects analysed) revealed enrichment in GO terms associated with 
platelet activation (Suppl. Table S3). GO terms of platelet aggregation, adhesion, degranulation, exocytosis and 
secretion, to name a few, were strongly and specifically enriched in the platelet arginine methylome compared to 
the whole platelet proteome, indicating relevant roles of ArgMe in platelet function. STRING analysis of the 
arginine methylome mapped out highly interconnected protein networks (Figure 1B). VASP was identified in 
only 2 PXD projects and was therefore not included in our arginine methylome. Given the central role of VASP 
in platelet signalling, we nevertheless immunoprecipitated VASP from human platelets and found that, firstly, 
VASP was recognised by anti-ArgMe antibodies (Suppl. Figure S1) and, secondly, mass spectrometry analysis 




Figure 1. Revealing the platelet arginine methylome. A. Decision pipeline towards a systematic analysis of 
ProteomeXchange datasets of the platelet proteome. B. STRING analysis of the platelet arginine methylome showing highly 
interconnected protein-protein interaction networks. Included in this panel are the proteins that were interconnected (54 out 
of 64), for a full list see Suppl. Table S2. ITGA2B and ITGB3 in the middle of the panel are the genes coding for the αIIb 
and β3 components of the fibrinogen receptor, respectively.  
 
ArgMe can be inhibited in platelets 
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To provide direct evidence that platelet proteins can be modified by ArgMe, we first tested for expression of the 
enzyme responsible for S-adenosylmethionine (SAM) synthesis (SAM synthase, MAT2A) and of PRMT1 in 
platelets. We observed bands at the expected molecular weights (MW), (Figure 2A, left). We also searched for 
protein ArgMe using western blot and we routinely observed several protein bands recognised by antibodies 
specific for mono- and di-ArgMe in platelet lysates (Figure 2A, right), although the identity of these proteins 
remains unknown.  
We then incubated platelets with Type I PRMT inhibitors in vitro and we observed reduced protein ArgMe 
profiles after 3-4 hours incubation with μM concentrations of furamidine and AMI-1 (Figures 2B and 2C and 
Suppl. Figure S2). For this reason, subsequent functional experiments (see below) were done following 
incubation of platelets with Type I PRMT inhibitors for 3-4 hours. We observed a dose-response relationship in 
the inhibition of ArgMe, shown by reduced intensity of ArgMe bands with increasing concentrations of 
furamidine (Figure 2D). Antibodies #8015 and #8711 were raised against different epitopes and it was therefore 
not surprising that they seemed to recognise different proteins, this was also shown in the original publication.22 
Incubation of platelets with PRMT inhibitors led to increased VASP phosphorylation at S157, a marker of platelet 
quiescence, although at lower levels than those observed after incubation with established platelet inhibitors such 




Figure 2. Platelet proteins are modified by ArgMe and incubation of platelets with PRMT inhibitors reduces ArgMe 
levels. A. Detection of MAT2A (expected MW: 43.6 kDa), PRMT1 (expected MW of the main isoform: 42.6 kDa) and 
ArgMe in platelet lysates using western blot. B. Incubation of platelets for 4 hours, but not 2 hours, with 1 mM AMI-1 led 
to ArgMe inhibition. C. Time-course of ArgMe inhibition by 10 µM furamidine, showing reduced ArgMe after 2-3 hours 
of incubation. D. Dose-response of ArgMe signals with increasing concentrations of furamidine, after a 4-hour incubation 
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period. E. Dose-response of VASP phosphorylation at Ser-157 with increasing concentrations of AMI-1, after a 4-hour 
incubation period. Representative blot (n = 3) and quantification of pS157-VASP relative to actin are shown. Stars indicate 
statistical significance (* p < 0.05). 
 
Inhibition of ArgMe impairs platelet aggregation 
Based on the GO term enrichment analysis of our platelet arginine methylome and on our biochemical data, we 
hypothesised that ArgMe plays a role in platelet aggregation. To test this hypothesis, we performed platelet 
aggregometry experiments in the presence of increasing amounts of PRMT1 inhibitors. We chose GSK3368715 
because it is currently in clinical trials (identifier: NCT03666988).19 We also used furamidine, AMI-1 and MS023 
as Type I PRMT inhibitors that have been developed in preclinical studies and used widely.23, 24 
We found dose-dependent inhibition of platelet aggregation after incubation of platelets with Type I 
PRMT inhibitors in vitro for 4 hours. We observed impaired platelet aggregation at low µM furamidine doses in 
response to thrombin (Figure 3A) or collagen (Suppl. Figure S3). We calculated IC50 values for the inhibition of 
platelet aggregation after thrombin stimulation in the low to mid µM range for furamidine, GSK3368715, MS023 
(Figure 3B and 3C) and AMI-1 (Suppl. Figure S4). Because the strongest effects were observed with furamidine, 
subsequent experiments were performed using this Type I PRMT inhibitor. 
Importantly, the inhibition of platelet aggregation by furamidine was at least partly reversible. Indeed, 
incubation of platelets with a maximum inhibitory dose of furamidine (80 μM) for 2 hours, followed by 2 hours 
incubation in the absence of furamidine, recovered an average of 33.5 ± 7.9% platelet aggregation across four 
donors (Figure 3D, see also Suppl. Figure S5 for representative aggregation curves). The reversibility of 
furamidine effects strongly suggested that platelets remained active and functional during incubation. To further 
support this view, we firstly analysed lactate dehydrogenase (LDH) release from platelets incubated with 
furamidine. LDH analysis showed that platelet integrity was maintained at all concentrations assayed (Suppl. 
Figure S6). Secondly, we visualised mitochondria in platelets and we found no changes in mitochondrial 





Figure 3. Furamidine causes a dose-dependent inhibition of platelet aggregation. A. Effect of furamidine on platelet 
aggregation stimulated by thrombin (0.1 U/ml). Platelet suspensions were incubated for 4 hours with the indicated 
concentrations of furamidine prior to stimulation. Traces are average of at least 6 independent experiments.  B and C. 
Visualisation of and calculated IC50 values for furamidine, MS023 and GSK3368715. D. The total inhibition of platelet 
aggregation by 80 µM furamidine (F) can be partly recovered by removing the inhibitor. Negative (-ve) control is platelets 
incubated with DMSO for 4 hours at 37°C. Positive (+ve) control is platelets incubated with furamidine (80 µM) for 4 
hours. Note the recovery of ca. 33.5% aggregation in platelets incubated first with 80 µM furamidine for two hours and 
11 
 
then with DMSO for 2 hours, compared to platelets incubated first with DMSO and then with furamidine. Individual data 
for four different donors are shown. Stars indicate statistical significance (** p < 0.005). 
 
Furamidine treatment leads to altered platelet spreading phenotype  
To assess for any effect of furamidine on platelet morphology, we assayed spreading on fibrinogen or collagen 
coated surfaces. We observed only very small and donor-dependent differences in total platelet numbers or cell 
surface area in samples treated with furamidine, with a trend towards slightly increased adhesion to fibrinogen 
and collagen with increased doses of the inhibitor (Figure 4 A-D). Consistent with this, treated platelets spread 
mainly through stress fibres and lamellipodia (78%) with a minority of actin nodules (16%), compared to a 
combined phenotype (33% stress fibres and 61% actin nodules) in untreated platelets (Figure 4E).  
 
Figure 4. Mild changes in spreading after incubation of platelets with furamidine. A-D. Number of platelets and 
platelet surface area on spreading onto fibrinogen (A and B) or collagen (C and D) in the absence (control) or in the presence 
of increasing concentrations of furamidine for 4 hours. Data are shown as the mean ± SD (error bars), with the data points 
from each donor (n = 3 donors for fibrinogen and n = 4 donors for collagen, five slides analysed from each donor) linked 
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to make donor-specific comparisons. Donors are colour coded. Statistical comparisons are shown between samples from 
the same donor. Stars indicating statistical relevance (* p < 0.05; ** p < 0.005) are coloured according to the donor where 
any difference between treated and control samples was found significant (ANOVA with post hoc Tukey tests). E. 
Representative images of platelets spreading on fibrinogen after treatment with a range of furamidine concentrations (4 
hours); all images are from the same donor. Inset: visualisation of spreading phenotype: actin nodules (dark grey), stress 
fibres (light grey) and mixed phenotype or non-classifiable (white).  
 
Expression and activation of key platelet receptors changes upon treatment with furamidine 
To identify any changes in expression or activation of key platelet proteins upon treatment with PRMT inhibitors 
that could explain the observations above, we performed flow cytometry experiments using platelets incubated 
with low furamidine concentrations (10 μM). There were no changes in the expression of the collagen receptors 
integrin α-2 (CD49b) and glycoprotein VI (GPVI), (Figure 5A). Consistent with the latter, phosphor-tyrosine 
(pY) signalling was not significantly affected by furamidine (Suppl. Figure S8). However, we observed 
significant (although small) reductions in the expression of the α-chain of the vWF binding complex GPIb 
(CD42b) and the critical integrin αIIb (CD41), (Figure 5A). We tested the effect of furamidine on the activation 
of the αIIbβ3 receptor by a range of agonists and found that furamidine impaired αIIbβ3 activation by thrombin, 
collagen related peptide (CRP), ADP and U46619, an agonist of the thromboxane receptor (Figure 5B).  
We also quantified secretion of dense and alpha granules following platelet activation, measured by CD63 
and P-selectin, respectively. Both experiments showed a general decrease in antibody binding following 
furamidine incubation, this decrease was statistically significant when platelets were stimulated with low and 
high doses of CRP (Figure 5C and 5D). Taken together, our results show that Type I PRMT inhibitors affect 





Figure 5. Furamidine treatment leads to changes in receptor expression and granule secretion. Analysis of the effect 
of 10 µM furamidine on the expression of (A) key platelet receptors, (B) activated αIIbβ3 receptor, (C) dense granule 
secretion and (D) alpha granule secretion. Colours and joined lines denote pairs of control and furamidine-treated platelets 
and white and grey bars are control and furamidine (at 10 µM for 4 hours) experiments, respectively. Data are shown as the 
mean ± SD (error bars), with the data points from each donor (n = 6 donors) colour-coded and linked to make pairwise 
comparisons. Stars indicate statistical significance (* p < 0.05; ** p < 0.005, paired Student’s t-test). 
 
Discussion 
Over the past few years, several groups have begun to identify the set of proteins modified by ArgMe, that is, the 
arginine methylome, in various cells and tissues,22, 25-28 however, the extent and role of ArgMe in platelets has 
not yet been investigated. Our work indicates that many proteins are modified by ArgMe in platelets. From that 
standpoint, we decided to investigate the effect of ArgMe inhibition on platelet function. PRMT inhibitors have 
been hailed as novel, promising drugs for the treatment of several cancer types. This is based on remarkable 
success in the synthesis of specific inhibitors and on encouraging preclinical and clinical models of disease,14, 29-
31 which have led to clinical trials by major pharmaceutical companies. The research community has appreciated 
the need to monitor any side-effects of these emerging class of drugs,32 and our work raises the need to consider 
platelet inhibition as a possible off-target effect of the systemic administration of PRMT inhibitors in ongoing 
and subsequent clinical trials.    
Incubation of platelets with PRMT inhibitors for 4 hours led to reduced levels of global ArgMe as judged 
by western analysis. This suggests that there is PRMT activity in washed platelets and that PRMT inhibitors can 
permeate platelet membranes relatively rapidly. We tested several PRMT1 (or more generally Type I PRMT) 
inhibitors including AMI-1, MS023, GSK3368715 and furamidine. We expected that MS023 and GSK3368715 
would inhibit ArgMe in platelets at the lowest concentrations, given their reported IC50 values against PRMT1 
(30 and 3.1 nM, respectively).19, 24 However, the largest effect on platelet aggregation was observed in the 
presence of low µM concentrations of furamidine, which has a reported PRMT1 IC50 value of 9.4 µM.
23 We 
hypothesise that this is due to active transport of furamidine into platelets through the organic cation transporter 
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1,33 which is expressed in platelets.34 Platelets cannot be maintained in cell culture and rapidly lose viability in 
vitro, which limits the time that washed platelets can be incubated with PRMT inhibitors. An obvious question 
that needs to be addressed in the future is the effect of systemic administration of therapeutic doses of PRMT1 
inhibitors on platelet function in animal models and clinical trials; especially given previous, limited reports of 
in vivo haematological effects of PRMT inhibitors in the µM range.19 One would expect that continued oral 
administration of PRMT inhibitors, for example of GSK3368715, during weeks lead to steady state concentration 
inside short-lived platelets and consequently ArgMe inhibition. Full-body and tissue specific PRMT knock-outs 
(KO) have been generated and present a wide range of defects, from embryonic lethality (PRMT1 and -5 KO) to 
only minor phenotypes,35 however, to our knowledge platelet dysfunction has not been reported in these models. 
It may be possible that mice platelets are less affected by PRMT downregulation or inhibition and it would be 
interesting to generate platelet specific PRMT1 KOs in the future to shed light onto this standing matter. 
While acknowledging the limitations of working with washed human platelets in vitro, we report 
moderate changes to platelet aggregation and mild changes to spreading and expression of key platelet receptors 
at low doses of furamidine. We observed impaired platelet aggregation in response to both thrombin and collagen. 
This is consistent with a decreased expression of αIIb at the cell membrane and reduced activation of the αIIbβ3 
receptor after incubation of platelets with 10 µM furamidine, both at basal conditions and when platelets were 
stimulated with agonists (thrombin, CRP, ADP and a thromboxane analogue). Of note, both components of the 
αIIbβ3 receptor were found to be methylated in platelets and it is tempting to speculate that inhibition of ArgMe 
may jeopardise αIIbβ3 docking at the cell membrane. It is known, for example, that ArgMe of certain membrane 
proteins, such as ion channels, stimulates protein trafficking to the cell membrane.36, 37 Alternatively, ArgMe may 
be associated with receptor stability or heterodimerisation. This can occur for instance through mediating protein-
protein interactions as it has been suggested for the endothelial growth factor receptor (EGFR),38 or through 
cross-talk with neighbouring modifications. For example, Y660 and K669 in β3 are modified by phosphorylation 
and ubiquitination, respectively,39, 40 and lie in the vicinity of R659, which we have identified as methylated, and 
there are many examples of cross-talk between ArgMe and neighbouring post-translational modifications that 
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can affect protein interactions, localisation and stability.14 In any event and given the central role of the αIIbβ3 
receptor in platelet function, further investigations of αIIbβ3 ArgMe are warranted. Some ArgMe sites, including 
those in both components of the αIIbβ3 receptor, were identified in extracellular domains. While less commonly 
reported than intracellular ArgMe sites, it is accepted that extracellular receptor domains, for example in EGFR, 
can be extensively methylated by PRMT1, presumably at the endoplasmic reticulum/Golgi compartments.38, 41, 
42  
We also observed a general trend towards a mild decrease of dense and alpha granule secretion after 
furamidine treatment, as judged by CD63 and P-selectin exposure. This is consistent with the inhibition of platelet 
aggregation,43 and also with the enrichment in the platelet arginine methylome of GO terms associated with 
platelet degranulation and secretion. We show very mild effects of furamidine on platelet adhesion. We observed 
a primed platelet phenotype upon treatment with furamidine, with a decrease in the number of actin nodules and 
an increase in the number of stress fibres. This is consistent with the enrichment in GO terms associated with the 
actomyosin cytoskeleton and stress fibres in the platelet arginine methylome. Proteins with these GO terms in the 
arginine methylome include myosins, tropomyosins and actinins. We report minor changes in the number of 
platelets and platelet surface area, but only in a couple of donors and furamidine doses. To bring together the 
significant effects of furamidine on platelet aggregation and on receptor expression with the mild spreading 
phenotype, we reason that furamidine must affect signalling downstream of the receptors. There are potentially 
many pathways that could be affected (for example, cyclic nucleotide dependent signalling, CalDAG-GEFI, Src 
family tyrosine kinases, cytoskeletal substrates) and decreased receptor levels may not fully explain the observed 
phenotype. For instance, platelet spreading on fibrinogen could be maintained in the context of reduced αIIbβ3 
activity if ArgMe inhibition enhances GPVI activation by immobilised fibrinogen.44 The combination of 
moderate effects of furamidine on platelet aggregation and a mild trend towards increasing platelet adhesion may 
be of interest towards repurposing PRMT inhibitors as potential, novel antiplatelet agents. However, this idea 
comes with its own caution note: it is conceivable that PRMT inhibitors also affect the morphology, signalling 
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and function of other cell entities and these effects cannot currently be predicted, especially for long-term 
treatments. 
Furamidine has been used as a specific PRMT1 inhibitor at low µM concentrations.23, 45-48 Furamidine is 
also known to have other effects including as an anti-protozoal agent,49 DNA binding and inhibitor of tyrosyl-
DNA phosphodiesterase 1.50 These alternative activities of furamidine are unlikely to be relevant in the context 
of washed or circulating platelets and furamidine treatment reduced the intensity of ArgMe bands, which supports 
the idea that the reported inhibition of platelet function is due to direct inhibition of PRMT activity. Furamidine 
is thought to bind to the substrate pocket on PRMT1 by mimicking the side-chain guanidino group of arginine 
with involvement of hydrogen bonding and electrostatic interactions,23, 51 and thus competes with the substrate 
and reversibly inhibits PRMT1. Consistent with this, the effects of maximal inhibitory doses of furamidine on 
platelet aggregation were at least partially reversed after a short wash-off.  
Taken together, our results open new avenues for research on ArgMe in platelets. Firstly, platelets, being 
anucleate cells, are a good model for research on ArgMe outside of the nucleus and our data show that tens of 
proteins, including critical platelet receptors, are modified by ArgMe in human platelets. Secondly, there may be 
an opportunity to develop inhibitors of specific ArgMe sites of platelet proteins, e.g. αIIbβ3, with possible 
therapeutic applications. Thirdly, we recommend that current and future clinical trials using PRMT inhibitors 
consider the investigation of platelet function and include the monitoring of possible adverse effects related to 
platelet inhibition. 
 
Materials and Methods 
Ethics Statement  
This work was completed in accordance with the University of Hull and Hull York Medical School (HYMS) 
ethical guidelines. Work with human blood samples, including platelets, was approved by the HYMS ethics 
committee and was completed under the ‘project 1501: The study of platelet activation, signalling and 
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metabolism’. All participants gave their informed consent prior to their inclusion in the study and the study 
conformed to the Declaration of Helsinki. 
Bioinformatics analysis of ProteomeXchange datasets 
The bioinformatic analysis of PXD projects was completed following published protocols.21 Briefly, all 
proteomic raw data in ProteomeXchange as for May 2020 were systematically searched using the following 
inclusion criteria: 1) inclusion of platelet proteomic data and 2) the data being from human samples. Exclusion 
criteria were: 1) datasets where enrichment e.g. phosphoenrichment had been performed and 2) unclear labelling 
of files. Datasets that fulfilled the study criteria were downloaded and mined for protein ArgMe using MaxQuant 
(v1.6.14.0). ArgMe was set as a variable modification together with Met oxidation and N-terminal protein 
acetylation. Cys carbamidomethylation was set as a fixed modification. MaxQuant parameters were left as default 
in searches against the human proteome downloaded from Uniprot (April 2020). The platelet arginine methylome 
was defined as those ArgMe sites identified in three or more PXD projects, after manual curation of the data to 
remove likely contaminants (e.g. keratins, immunoglobulins). Enrichment in gene ontology (GO) terms in the 
platelet arginine methylome was assessed using GOrilla,52 using the platelet proteome as background set and the 
platelet arginine methylome as the target set. STRING analysis of protein networks was done online 
(https://string-db.org/) using high confidence interaction scores (0.7) and all available interaction sources.53 
PRMT inhibitors and reagents 
MS023 and furamidine were purchased from Tocris, AMI-1 was from Sigma-Aldrich and GSK3368715 was 
purchased from Cambridge Bioscience. Stock solutions of all ArgMe inhibitors were at 50 mM concentration in 
DMSO. Thrombin, ADP, fibrinogen and FITC-conjugated phalloidin were from Sigma-Aldrich. Collagen was 
purchased from Takeda. MitoTracker red CMXRos was from ThermoFisher Scientific. Other reagents were from 
Sigma-Aldrich unless indicated otherwise. 
Platelet isolation and incubation with PRMT inhibitors 
Blood (20-80 ml) was collected from healthy donors through venepuncture into acid citrate dextrose (29.9 mM 
trisodium citrate, 113.8 mM glucose, 72.6 mM NaCl, 2.9 mM citric acid, pH 6.4) and centrifuged at 190×g for 
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15 min at room temperature to obtain platelet rich plasma, as previously reported.54 Platelets were pelleted further 
by centrifugation at 800×g for 12 min in the presence of 6 mM citric acid, washed (0.036 M citric acid, 0.01 M 
EDTA, 0.005 M glucose, 0.005 M KCl, 0.09 M NaCl, pH 6.5) and centrifuged as before. Pelleted platelets were 
resuspended in modified Tyrode’s buffer (150 mM NaCl, 5 mM HEPES, 0.55 mM NaH2PO4, 7 mM NaHCO3, 
2.7 mM KCl, 0.5 mM MgCl2, 5.6 mM glucose, pH 7.4) and maintained at 37°C for 30 min in preparation for 
experiments. Platelets were incubated with PRMT inhibitors or vehicle (DMSO) for 3-4 hours at 37°C unless 
indicated otherwise. 
Platelet aggregation  
Platelet aggregation in response to agonists was recorded at a concentration of 3x108 platelets / ml under constant 
stirring conditions (1000 rpm) for 4 min at 37 °C using Born aggregometry.11, 55 For the reversibility experiments, 
we incubated platelets with 80 µM furamidine (or vehicle) for 2 hours, and then on ice for 5 minutes. Platelets 
were then centrifuged for 50 seconds at 3600×g. The supernatant was removed and the platelets resuspended in 
modified Tyrode’s buffer at room temperature. Only one wash was performed. Platelets were then incubated at 
37 °C for the remaining 2 hours with vehicle or 80 µM furamidine as appropriate. Aggregations were completed 
with 0.1 U/ml thrombin or 10 µg/ml collagen.  
Platelet spreading  
For platelet spreading analysis, untreated or furamidine-treated platelets (2 × 107/ml) were spread on fibrinogen 
or collagen (both at 100 µg/ml) coated coverslips at 37°C for the specified times. Platelets were fixed in 4% 
paraformaldehyde solution for 10 minutes and then permeabilised in 0.1% Triton X-100 for 5 minutes. Slides 
were stained with FITC-phalloidin for 1 hour for F-actin visualisation, washed, and imaged on a Zeiss Axio 
Imager fluorescence microscope with a 63× 1.4NA oil immersion objective.54, 56 Platelet numbers, actin 
nodule/stress fibre ratios and surface areas were measured using ImageJ (NIH).  
Western blot 
Platelet lysates (30-60 µg in 1% SDS) were resolved by 10-12% SDS-PAGE and transferred to nitrocellulose 
membranes. Membranes were probed with antibodies targeting mono-ArgMe (#8015 and #8711, Cell Signalling 
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Technologies), di-ArgMe (#13522, Cell Signalling Technologies), VASP, α-MAT2A and α-PRMT1 (Abcam) 
and phosphor-tyrosine (#05-321, Sigma) as appropriate, with GAPDH or β-actin (Thermo) as loading control. 
Blots were developed using enhanced chemiluminescence reagents (Luminata Forte, Millipore) and signals 
visualised and captured on a ChemiDoc (Bio-Rad). Blots shown are representative of at least two independent 
experiments. Quantitative data drawn from western blots are derived from at least n = 3 experiments. 
Densitometry analysis was done using ImageJ (NIH).  
Mass spectrometry analysis of VASP 
VASP was immunoprecipitated from platelets using specific antibodies (#ab109321, Abcam) and the 
immunoprecipitate resolved through SDS-PAGE. The putative Coomassie-stained VASP band was digested with 
Lys-C protease after reduction with dithioerythritol and alkylation with iodoacetamide. The resulting peptides 
were analysed by LC-MS/MS using an Orbitrap Fusion mass spectrometer with elution from a 50 cm PepMap 
column over a 35 min gradient.  All MS/MS samples were analysed using Mascot (version 2.6.1) and X! Tandem 
(version CYCLONE 2010.12.01.1). Searches was set up against the UniProt human FASTA database (June 2014, 
20259 entries) using Lys-C as the protease. Mascot and X! Tandem were searched with a fragment ion mass 
tolerance of 0.50 Da and a parent ion tolerance of 3.0 ppm. Cys carbamidomethylation was specified in Mascot 
and X! Tandem as a fixed modification. Deamidation of Asn and Gln, methylation of Arg, oxidation of Met and 
acetylation of protein N-termini were specified in Mascot as variable modifications. Glu->pyro-Glu, ammonia-
loss, acetylation and Gln->pyro-Glu of the N-termini, deamidation of Asn and Gln, methylation of Arg and 
oxidation of Met were specified in X! Tandem as variable modifications. Peptide and protein identifications were 
filtered in Scaffold (version Scaffold_4.8.2) to require a global false discovery rate of <1% at both the protein 
and peptide level.  Protein matches required a minimum of two unique peptide identifications. Peptide 
identifications were accepted if they could be established at greater than 90.0% probability to achieve an FDR 




For flow cytometry analysis of platelet receptors, platelets were incubated with 10 µM furamidine for a period of 
4 hours before fixing (20% paraformaldehyde, BD Phosflow) and staining with antibodies. The antibodies were 
from BioLegend against the following targets: CD49b (#359309), GPVI (clone HIM3-4, #303302), CD42b (clone 
HIP1, #303903), CD41 (clone A2A9/6, #359805), active αIIbβ3 receptor (PAC1, #362803), CD63 (clone H5C6, 
353005) and P-selectin (clone AK4, #304905). Analysis of the stained platelets was completed using a LSR 
FortessaTM from BD Biosciences, and data was analysed with FlowJo. 
LDH assays 
Lactate dehydrogenase (LDH) assays were done following the instructions of the cytotoxicity detection KitPLUS 
(LDH) (Roche). Briefly, platelets were lysed in 1% Triton X-100 in 96-well plates (n = 3 independent 
experiments, 2 technical replicates), the LDH reaction mixture (diaphorase, NAD+ and sodium lactate) was added 
to each well and the plate was incubated at 37°C for 30 minutes in the dark. Reactions were stopped by 1 M HCl 
and the plate was read at 490 nm with a correction of 680 nm using a spectrophotometer. 
Statistical analysis 
Data were analysed using paired student’s T-tests (flow cytometry experiments), or one-way ANOVA (with post 
hoc Tukey for pairwise comparisons) as appropriate, with statistical significance defined as p < 0.05. Stars in 
figures define statistical significance. 
 
Supporting Information. Supplementary Figure S1: VASP is modified by ArgMe in human platelets. 
Supplementary Figure S2. Incubation of platelets with 1 mM AMI-1 for 4 hours leads to inhibition of protein 
ArgMe. Supplementary Figure S3. Furamidine causes the dose-dependent inhibition of platelet aggregation 
stimulated by collagen. Supplementary Figure S4. AMI-1 inhibits platelet aggregation. Supplementary Figure 
S5. Representative example of raw aggregation curves in reversibility experiments. Supplementary Figure S6. 
LDH assay demonstrates platelet integrity upon incubation with increasing concentrations of furamidine. 
Supplementary Figure S7. Furamidine does not impair mitochondrial membrane potential. Supplementary Figure 
S8. Furamidine does not lead to changes in phosphor-tyrosine (pY) signalling. Supplementary Table 1. Identity 
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of the 13 PXD projects included in our bioinformatics analysis. Supplementary Table 2. Curated list of proteins 
modified by ArgMe in platelets, that is, the arginine methylome. Supplementary Table 3. GO enrichment analysis 
in the subset of proteins modified by ArgMe in three or more PXD projects. Supplementary Table 4. Mass 
spectrometry identification of VASP and R10 methylation. 
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Brief synopsis: 
Protein arginine methyltransferases (PRMT) inhibitors are very novel drugs against cancer that are currently in 
clinical trials, however, off-target activities of systemically available PRMT inhibitors have not yet been fully 
investigated. In this work, we have studied the effect of PRMT inhibitors on human platelet molecular and 
functional phenotypes. We recommend that current and future clinical trials with PRMT inhibitors consider any 
effects associated with platelet inhibition of these promising anti-cancer drugs. 
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